- Home
- SAVA vs CNVS Comparison
SAVA vs CNVS Comparison
Compare SAVA & CNVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- CNVS
- Stock Information
- Founded
- SAVA 1998
- CNVS 2000
- Country
- SAVA United States
- CNVS United States
- Employees
- SAVA N/A
- CNVS N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- CNVS Consumer Electronics/Video Chains
- Sector
- SAVA Health Care
- CNVS Consumer Discretionary
- Exchange
- SAVA Nasdaq
- CNVS Nasdaq
- Market Cap
- SAVA 102.4M
- CNVS 102.4M
- IPO Year
- SAVA N/A
- CNVS 2003
- Fundamental
- Price
- SAVA $2.16
- CNVS $3.71
- Analyst Decision
- SAVA Hold
- CNVS Buy
- Analyst Count
- SAVA 1
- CNVS 1
- Target Price
- SAVA $2.00
- CNVS $10.00
- AVG Volume (30 Days)
- SAVA 607.2K
- CNVS 418.8K
- Earning Date
- SAVA 11-06-2025
- CNVS 08-14-2025
- Dividend Yield
- SAVA N/A
- CNVS N/A
- EPS Growth
- SAVA N/A
- CNVS N/A
- EPS
- SAVA N/A
- CNVS 0.13
- Revenue
- SAVA N/A
- CNVS $80,173,000.00
- Revenue This Year
- SAVA N/A
- CNVS $1.28
- Revenue Next Year
- SAVA N/A
- CNVS N/A
- P/E Ratio
- SAVA N/A
- CNVS $27.78
- Revenue Growth
- SAVA N/A
- CNVS 77.07
- 52 Week Low
- SAVA $1.15
- CNVS $0.72
- 52 Week High
- SAVA $33.98
- CNVS $7.39
- Technical
- Relative Strength Index (RSI)
- SAVA 45.76
- CNVS 30.05
- Support Level
- SAVA $2.12
- CNVS $3.51
- Resistance Level
- SAVA $2.40
- CNVS $5.39
- Average True Range (ATR)
- SAVA 0.10
- CNVS 0.37
- MACD
- SAVA -0.01
- CNVS -0.16
- Stochastic Oscillator
- SAVA 17.24
- CNVS 10.42
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
About CNVS Cineverse Corp.
Cineverse Corp is a main streaming technology and entertainment company. Its core business operates as a portfolio of owned and operated streaming channels with enthusiast fan bases; a large-scale aggregator and full-service distributor of feature films and television programs; and a proprietary technology software-as-a-service platform for over-the-top (OTT) app development and content distribution through subscription video-on-demand (SVOD), dedicated ad-supported (AVOD), ad-supported streaming linear (FAST) channels, social video streaming services, and audio podcasts. It generates revenue from streaming and digital, Base distribution, Podcast and other, and Other non-recurring.